BUSINESS● LOWAug 27 · Aug 27, 2026, 12:43 PM
Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials
Yahoo Finance
Regeneron Pharmaceuticals is adjusting its strategy following mixed results in its melanoma drug trials. This indicates a change in direction for the company's pharmaceutical development efforts.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS9m agoFirm pushes to revive Nigeria cocoa industry with 45 , 000mtt – Daily Trustdailytrust.com · NigerBUSINESS9m agoRegulatory Standards Board makes first findings – LiveNews . co . nzlivenews.co.nz · New Zealand